267537 ACA overview: The top ten things you need to know about health care reform in the US

Monday, October 29, 2012 : 12:30 PM - 12:50 PM

Dana Thomas , Nfprha, National Family Planning and Reproductive Health Association, Washington, DC
In anticipation of the seismic changes coming to health care delivery and financing initiated by the Affordable Care Act (ACA), family planning providers will need to adapt and change. The National Family Planning & Reproductive Health Association (NFPRHA) has advanced several “viable paths” through health care reform for its members to consider. NFRPHA has developed case studies to support business models that are more likely paths to success. Recognizing there may be no one right path and not every path is viable for every provider setting, the presenters will share insights into the options available for these safety-net providers to succeed under the ACA.

Learning Areas:
Administration, management, leadership
Provision of health care to the public

Learning Objectives:
Explain the impacts of ACA on the publicly supported family planning network. Identify business models as paths to viability for family planning. Discuss steps provider organizations might take to implement the viable paths.

Keywords: Family Planning, Health Reform

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Dana Thomas is the Senior Policy Director at National Family Planning & Reproductive Health Association (NFPRHA). NFPRHA’s members operate a network of more than 3,700 health centers and service sites that provide comprehensive family planning services to millions of low-income individuals in 48 states and the District of Columbia. She was previously Legislative Counsel at U.S. House of Representatives. She received her J.D. and a Certificate in Health Policy from the George Washington University.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 3259.0: State of the field: health care reform and implications for reproductive health